Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

Novartis (NVS) has demonstrated significant outperformance within the Medical sector this year, achieving a 26.2% year-to-date return against the sector's average of -2.6% and its Large Cap Pharmaceuticals industry's 0%. This strong showing is underpinned by a Zacks Rank #2 (Buy) and a 1.9% increase in its full-year earnings estimate over the last 90 days, reflecting positive analyst sentiment. Arbutus Biopharma (ABUS) is also highlighted as a notable outperformer, with a 34.6% YTD return and a 15.6% rise in current year EPS estimates.

Analysis

Novartis (NVS) has demonstrated significant market outperformance year-to-date, posting a 26.2% return that starkly contrasts with the -2.6% average return of the broader Medical sector and the 0% average gain of its Large Cap Pharmaceuticals industry peers. This relative strength is supported by fundamental indicators, including a Zacks Rank of #2 (Buy), which suggests a favorable outlook for the next one to three months. A key driver behind this rating is improving analyst sentiment, evidenced by the 1.9% increase in the Zacks Consensus Estimate for NVS's full-year earnings over the past 90 days. The article also highlights Arbutus Biopharma (ABUS) as another strong performer within the medical field, with a 34.6% year-to-date gain and a substantial 15.6% increase in its current-year consensus EPS estimate, reinforcing the theme that specific stocks with positive earnings estimate revisions can significantly outperform even in a lackluster sector.

Key Decisions for Investors

• Given Novartis's significant outperformance and positive earnings revisions, investors with existing positions may consider it a core holding, while those seeking exposure to large-cap pharma could view it as a candidate with demonstrated momentum.
• The bullish case for NVS is heavily tied to its Zacks Rank #2 (Buy) and the underlying trend of upward earnings estimate revisions; therefore, investors should closely monitor for any change in this rank or a reversal in analyst sentiment.
• The similar outperformance of Arbutus Biopharma suggests a strategy of screening the Medical sector for other stocks with a Zacks Rank of #1 or #2 and recent positive estimate revisions to identify other potential alpha-generating opportunities.